No early-detection tool currently exists to identify ovarian cancer in women. But a clinical trial at Carol G. Simon Cancer Center may change the standard of care for this silent disease and lead to routine screening for all women.
"It’s easier to treat ovarian cancer if identified at an early stage, but over 75 percent of women are diagnosed with advanced stage disease,” says Brian Slomovitz, MD, director of research for Carol G. Simon Cancer Center and associate director of the Women’s Cancer Center. “This clinical trial is the best study available to screen low-risk women for this deadly disease.”
Morristown and Overlook will be the only regional medical centers included in this innovative study with MD Anderson Cancer Center at the University of Texas that employs a new Risk of Ovarian Cancer Algorithm (ROCA) – a mathematical model using a woman’s age, weight, etc. and CA-125 score. Based on preliminary results, investigators believe this study will yield an effective tool for early detection of ovarian cancer.
To offer your support, please contact either Noelle Deihl-Harteveld at 973-593-2409,
noelle.harteveld@atlantichealth.org or Hyona Revere, director of major gifts, at 973-593-2429,
hyona.revere@atlantichealth.org.